By PPN News Staff
The FDA Oncologic Drugs Advisory Committee has recommended that Pfizer’s epoetin alfa biosimilar be approved across all indications. This marks the first time that a biosimilar erythropoiesis-stimulating agent has been recommended for approval by an FDA advisory committee.